LIVE
DXCM
DexCom, Inc. · Health Care - Medical Devices / Diabetes Technology
$72.47
+8.24% this month
VERSUS
⟷
COMPARE
TNDM
Tandem Diabetes Care, Inc. · Health Care - Medical Devices / Diabetes Technology
$15.30
+10.39% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
DXCM
3
TNDM
1
Comparison scoreboard
DXCM LEADS 3/5AI Score
DXCM ✓50.6
TNDM 24.9
1Y Return
DXCM ✓-11.44%
TNDM -25.02%
Fwd P/E
DXCM ✓24.45
TNDM 260.20
Target Up.
DXCM +12.33%
TNDM ✓+90.85%
Op. Margin
DXCM 21.42%
TNDM N/A
Metrics last refreshed: 6/20/2026
Quick take
DXCM vs TNDM Stock Comparison: AI Score, Valuation, Performance and Upside
DXCM and TNDM are complementary diabetes technology companies whose devices integrate to create closed-loop automated insulin delivery systems. Dexcom provides the glucose sensing, while Tandem provides the insulin pump with the Control-IQ algorithm that acts on Dexcom's data. Dexcom is the larger, faster-growing platform while Tandem faces more competitive pressure in insulin pumps.
DXCM vs TNDM covers complementary diabetes technology platforms — Dexcom's glucose sensor leadership and massive Type 2 expansion opportunity against Tandem's AID insulin pump competing in a smaller but clinically important market.
Live analysis · updated 6/20/2026
DXCM holds the edge across 3 of 5 key metrics in this comparison. DXCM leads on both 1-year return (-11.44%) and forward P/E (24.45x vs 260.20x for TNDM), a relatively favorable combination of momentum and valuation. Analyst consensus implies meaningfully more upside for TNDM (+90.85%) than for DXCM (+12.33%).
Normalized 1Y performance
DXCM
TNDM
Recent returns
DXCM
TNDM
Analyst price targets & sentiment
DXCM · 25 analysts
STRONG BUYHOLDSTRONG SELL
Strong Buy (1.5/5.0)
Price target range
analyst low$82.00
analyst high$110.00
analyst mean$84.67
current price$72.47
+12.3% upside to analyst mean
TNDM · 20 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$17.00
analyst high$50.00
analyst mean$29.20
current price$15.30
+90.8% upside to analyst mean
Who should consider this stock?
DXCM may suit investors who:
- →Want the leading CGM platform with established Type 1 dominance and a massive Type 2 expansion opportunity ahead
- →Value Dexcom's G7 technology upgrade as improving competitive positioning versus Abbott FreeStyle Libre
- →See CGM adoption in the broader diabetes population (not just insulin-dependent) as a decades-long growth runway
TNDM may suit investors who:
- →Want insulin pump technology exposure with an automated insulin delivery (AID) system respected by endocrinologists and patients
- →Value Tandem's Control-IQ algorithm clinical performance and software update capability as technology differentiators
- →See Mobi launch as expanding Tandem's addressable market into the tubeless patch pump segment
Performance & AI score
| Metric | DXCM | TNDM |
|---|---|---|
| AI score | 50.6 | 24.9 |
| AI rank | #434 | #2940 |
| Latest close | $72.47 | $15.30 |
| 1M return | +8.24% | +10.39% |
| 6M return | +10.22% | -31.76% |
| 1Y return | -11.44% | -25.02% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | DXCM | TNDM |
|---|---|---|
| 1Y ago | $8.95K (-10.5%) started 2025-06-18 | $7.5K (-25.0%) started 2025-06-18 |
| 5Y ago | $6.85K (-31.5%) started 2021-06-21 | $1.63K (-83.7%) started 2021-06-18 |
| 10Y ago | $37.53K (+275.3%) started 2016-06-20 | $2.04K (-79.6%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | DXCM | TNDM |
|---|---|---|
| Market cap | $29.08B | $1.05B |
| Trailing P/E | 32.35 | N/A |
| Forward P/E | 24.45 | 260.20 |
| Price/Sales | 8.19 | 1.02 |
| EV/Revenue | 5.82 | 1.27 |
| Analyst target | $84.67 | $29.20 |
| Target upside | +12.33% | +90.85% |
Growth, profitability & risk
| Metric | DXCM | TNDM |
|---|---|---|
| Revenue growth | 15.00% | 5.50% |
| Earnings growth | 92.20% | N/A |
| EPS growth | +92.20% | N/A |
| FCF margin | +21.93% | -1.97% |
| Operating margin | 21.42% | N/A |
| Profit margin | 19.31% | -9.20% |
| ROIC proxy | 35.62% | -65.73% |
| Return on equity | 35.62% | -65.73% |
| Dividend yield | N/A | 0.00% |
| Beta | 1.44 | 1.57 |
| Debt/equity | 46.83 | 554.92 |
| Current ratio | 1.95 | 3.58 |
| Quick ratio | 1.58 | 2.87 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
DXCM max drawdown38.75%
TNDM max drawdown54.64%
DXCM max wkly drop17.22%
TNDM max wkly drop34.40%
5Y risk snapshot
DXCM max drawdown66.32%
TNDM max drawdown93.40%
DXCM max wkly drop42.68%
TNDM max wkly drop43.11%
10Y risk snapshot
DXCM max drawdown66.32%
TNDM max drawdown97.44%
DXCM max wkly drop42.68%
TNDM max wkly drop67.77%
Performance metrics by period
| Period | Metric | DXCM | TNDM |
|---|---|---|---|
| 1Y | Growth | -10.54% | -25.02% |
| CAGR | -10.56% | -25.03% | |
| Sharpe ratio | -0.18 | -0.04 | |
| Max drawdown | 38.75% | 54.64% | |
| Max daily drop | 14.63% | 19.94% | |
| Max wkly drop | 17.22% | 34.40% | |
| 5Y | Growth | -31.48% | -83.68% |
| CAGR | -7.29% | -30.42% | |
| Sharpe ratio | -0.01 | -0.26 | |
| Max drawdown | 66.32% | 93.40% | |
| Max daily drop | 40.66% | 35.25% | |
| Max wkly drop | 42.68% | 43.11% | |
| 10Y | Growth | +275.30% | -79.63% |
| CAGR | +14.15% | -14.72% | |
| Sharpe ratio | 0.43 | 0.14 | |
| Max drawdown | 66.32% | 97.44% | |
| Max daily drop | 40.66% | 58.88% | |
| Max wkly drop | 42.68% | 67.77% |
Business comparison
| Category | DXCM | TNDM |
|---|---|---|
| Company | DexCom, Inc. | Tandem Diabetes Care, Inc. |
| Sector | Healthcare | Health Care - Medical Devices / Diabetes Technology |
| Industry | Medical Devices | N/A |
| Core business | Dexcom designs and markets wearable continuous glucose monitoring (CGM) systems that measure blood glucose levels in real time using a small sensor worn on the body, providing real-time readings and trend alerts to patients and caregivers without fingerstick blood tests. | Tandem Diabetes Care develops t:slim X2 insulin pumps with the Control-IQ closed-loop automated insulin delivery (AID) algorithm, integrating with CGM sensors (including Dexcom) to automatically adjust basal insulin delivery to maintain glucose in range. |
| Investor focus | Investors track Dexcom's revenue growth in Type 1 and Type 2 diabetes users, expansion into Type 2 non-insulin users (a massive untapped market), G7 sensor adoption driving ASP improvements, and global market expansion. | Investors track Tandem's new pump shipments, installed base growth, Control-IQ international adoption, Mobi tubeless pump launch traction, and the company's revenue per unit and path toward profitability. |
DXCM strengths
- →CGM has become the standard of care for Type 1 diabetes management — Dexcom is the leading CGM provider with the most clinically validated system
- →G7 is a smaller, more accurate, more comfortable sensor than predecessors, improving competitive positioning versus Abbott FreeStyle Libre
- →Type 2 diabetes expansion represents a massive market opportunity — hundreds of millions of Type 2 patients globally could benefit from CGM
TNDM strengths
- →Control-IQ AID algorithm is highly regarded by endocrinologists and patients for its clinical performance in maintaining time-in-range glucose control
- →Tandem's t:connect app and software update capability (over-the-air pump updates) provide a technology differentiation in the insulin pump market
- →Mobi launch addresses the tubeless patch pump market segment dominated by Insulet's Omnipod
Risks to watch — DXCM
- →Abbott FreeStyle Libre is a strong, lower-cost CGM competitor that has gained significant market share globally and threatens Dexcom in Type 2 expansion
- →CGM sensor pricing faces ongoing reimbursement pressure from payers and potential commoditization risk as technology matures
- →Manufacturing scale-up for the large Type 2 market opportunity requires significant capital investment
Risks to watch — TNDM
- →Insulet's Omnipod DASH and Omnipod 5 tubeless AID system compete directly for users who prefer patch pumps over traditional tubed pumps
- →Pump market is maturing and requires ongoing technology differentiation to sustain new customer growth
- →Competition from Abbott and Medtronic integrated systems could reduce Tandem's CGM integration flexibility advantage
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →